- Home
- GOVX
GOVX
GeoVax Labs Inc.
as 12-18-2024 1:37pm EST
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors.
| Founded: | 2001 | Country: | United States |
| Employees: | N/A | City: | SMYRNA |
| Market Cap: | 23.8M | IPO Year: | N/A |
| Target Price: | $14.20 | AVG Volume (30 days): | 721.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -7.44 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.09 - $11.18 | Next Earning Date: | 11-12-2024 |
| Revenue: | $3,090,161 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 159.12% |
Latest GeoVax Labs Inc. News
GOVX Breaking Stock News: Dive into GOVX Ticker-Specific Updates for Smart Investing
GlobeNewswire
9 days ago
GeoVax Receives Notice of Allowance For Cancer Vaccine Patent
GlobeNewswire
22 days ago
GeoVax to Present at the Noble Capital Markets Twentieth Annual Emerging Growth Equity Conference
GlobeNewswire
a month ago
GeoVax Announces Positive Interim Data Review for Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia
GuruFocus.com
a month ago
Geovax Labs Inc (GOVX) Q3 2024 Earnings Call Highlights: Strategic Advances and Financial Challenges
GlobeNewswire
a month ago
GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update
TipRanks
a month ago
GeoVax Labs initiated with a Buy at Alliance Global Partners
GlobeNewswire
a month ago
GeoVax to Report Third Quarter 2024 Financial Results and Provide Corporate Update on November 12, 2024
GuruFocus.com
2 months ago
Geovax Labs Inc (GOVX) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial ...
Compare GOVX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GOVX GeoVax Labs Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.